The University of Tokyo · Medicine
Professor Toshimasa Yamauchi's research lab focuses on the molecular mechanisms underlying insulin sensitivity, energy homeostasis, and metabolic regulation, with a particular emphasis on adipokines such as adiponectin and nuclear receptors like PPARgamma. The lab investigates how these regulators influence glucose metabolism, lipid metabolism, and insulin signaling pathways in obesity and type 2 diabetes. Using genetically modified mouse models, including transgenic and knockout strains, the lab explores the functional roles of key metabolic regulators such as IRS-1, IRS-2, and PPARgamma variants in maintaining metabolic health. Their work aims to identify novel therapeutic targets for treating metabolic disorders through modulation of adipokine signaling and nuclear receptor activity.
Figures are computed from collected data and may differ slightly.
The adipocyte-derived hormone adiponectin has been shown to play important roles in the regulation of energy homeostasis and insulin sensitivity. In this study, we analyzed globular domain adiponectin (gAd) transgenic (Tg) mice crossed with leptin-deficient ob/ob or apoE-deficient mice. Interestingly, despite an unexpected similar body weight, gAd Tg ob/ob mice showed amelioration of insulin resistance and beta-cell degranulation as well as diabetes, indicating that globular adiponectin and lept
Peroxisome proliferator-activated receptor (PPAR) gamma is a ligand-activated transcription factor and a member of the nuclear hormone receptor superfamily that is thought to be the master regulator of fat storage; however, the relationship between PPARgamma and insulin sensitivity is highly controversial. We show here that supraphysiological activation of PPARgamma by PPARgamma agonist thiazolidinediones (TZD) markedly increases triglyceride (TG) content of white adipose tissue (WAT), thereby d
PPARgamma is a ligand-activated transcription factor and functions as a heterodimer with a retinoid X receptor (RXR). Supraphysiological activation of PPARgamma by thiazolidinediones can reduce insulin resistance and hyperglycemia in type 2 diabetes, but these drugs can also cause weight gain. Quite unexpectedly, a moderate reduction of PPARgamma activity observed in heterozygous PPARgamma-deficient mice or the Pro12Ala polymorphism in human PPARgamma, has been shown to prevent insulin resistanc
We and others recently generated mice with a targeted disruption of the insulin receptor substrate 1 (IRS-1) gene and demonstrated that they exhibited growth retardation and had resistance to the glucose-lowering effect of insulin. Insulin initiates its biological effects by activating at least two major signalling pathways, one involving phosphatidylinositol 3-kinase (PI3-kinase) and the other involving a ras/mitogen-activated protein kinase (MAP kinase) cascade. In this study, we investigated
Open papers in the app to read, cite, and organize with AI.
